Description of CPT code 38225, 38226, 38227 & 38228
We have new CPT codes for Chimeric antigen receptor (CAR-T) therapy in 2025 and it will be used from new year. Below is the coding description for these codes.
CPT 38225 – Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day
CPT 38226 – ; preparation of blood derived T lymphocytes for transportation (e.g. cryopreservation, storage)
CPT 38227 – ; receipt and preparation of CAR-T cells for administration
CPT 38228 – CAR-T cell administration, autologous
Chimeric Antigen Receptor T-cell (CAR-T) therapy is an advanced form of immunotherapy primarily used to treat blood cancers, such as leukemia. This treatment involves the use of genetically modified T cells, which are a type of white blood cell produced by the thymus and play a critical role in the immune system’s defense mechanisms.
The process begins with the collection of T cells from the patient through a procedure known as apheresis. During apheresis, the patient’s blood is drawn, and plasma, platelets, and white blood cells are separated and removed, while the remaining blood components are returned to the patient.
Once the T cells are collected, they are transported to a specialized facility where they are genetically engineered by introducing DNA that prompts the production of Chimeric Antigen Receptors (CARs). These receptors enable the T cells to recognize and target cancerous cells by identifying specific antigens present on the surface of these malignant cells. The engineered T cells, now referred to as CAR-T cells, are expanded in the laboratory to generate a sufficient number of cells. Afterward, the CAR-T cells are cryopreserved until the patient is ready for treatment.
Prior to infusion, patients may undergo a brief course of chemotherapy to deplete existing lymphocytes and T cells. Once prepared, the CAR-T cells are reintroduced into the patient’s bloodstream, where they multiply and actively seek out and destroy cancer cells expressing the targeted antigen. The CAR-T cells can remain in the body for months following treatment, providing extended remission periods.
The specific steps of the CAR-T therapy process are represented by the following codes:
- CPT code 38225 for the collection of blood-derived T lymphocytes
- CPT code 38226 for the preparation of T lymphocytes for transportation
- CPT code 38227 for receiving and preparing the cells for administration
- CPT code 38228 for the administration of the genetically engineered CAR-T cells.
It is important to note that the collection, handling, and administration services should only be reported once per day, regardless of the number of cells collected or units administered.